INV SUPERIOR JUBILADO
SEILICOVICH Adriana
congresos y reuniones científicas
Título:
Therapeutic blockade of Foxp3 using gene therapy vectors
Autor/es:
A.J.NICOLA CANDIA; M.MORENO AYALA; F.GOTTARDO; A.ASAD; C.ZUCCATO; E. BAL DE KIER JOFFE; A. SEILICOVICH; F.ZANETTI; M.CANDOLFI
Lugar:
CABA
Reunión:
Congreso; Reunión conjunta de Sociedades de Biociencia; 2017
Resumen:
Our previous results indicate that systemic administration of a cell penetrating peptide (P60) that inhibits Foxp3, a transcription factor required for Treg function, improves the efficacy of antitumor vaccines in experimental breast cancer. Although there is controversy over the role of Foxp3 in tumor cells, we found that P60 inhibits survival and trelease of IL-10 in Foxp3+ breast tumor cells. Here we aimed to evaluate the regulatory pathways that control Foxp3 expression in LM3 breast tumor cells and to develop gene therapy vectors encoding P60. We assessed the effect of recombinant TGF-β, mTOR inhibitor rapamycin and COX-2 inhibitor indomethacin, all of which have been shown to modulate Foxp3 expression in Tregs. Stimulation of LM3 cells with TGF-β and rapamicyn upregulated Foxp3 expression (p